Last reviewed · How we verify

Opioid Analgesic

Vanderbilt University Medical Center · FDA-approved active Small molecule

Opioid analgesics bind to opioid receptors in the central and peripheral nervous system to reduce the perception of pain.

Opioid analgesics bind to opioid receptors in the central and peripheral nervous system to reduce the perception of pain. Used for Moderate to severe acute pain, Chronic pain management.

At a glance

Generic nameOpioid Analgesic
Also known asConventional Opioid based analgesia
SponsorVanderbilt University Medical Center
Drug classOpioid analgesic
TargetOpioid receptors (mu, delta, kappa)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

These drugs activate mu, delta, and kappa opioid receptors, which modulate pain signaling pathways and alter the emotional response to pain. By binding to these G-protein coupled receptors, opioids decrease neurotransmitter release and hyperpolarize neurons, resulting in analgesia, sedation, and euphoria.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: